Nearly one in four 'high-risk' breast cancer patients are safer than they feared — and an AI test just proved it blind

An AI test that reads a routine pathology slide has passed a tough, independent check. Researchers at Karolinska Institutet in Sweden, working blind — without knowing any patient's outcome — ran the myStage Dx test on 620 women from the PANTHER trial, all considered clinically high-risk. The test picked out a group making up 23.5% of the women whose outlook was far brighter: ten years on, an estimated 96.1% of them were alive and free of recurrence, compared with 76.6% of the rest. For those women, clearer risk information could mean calmer decisions about extra years of treatment, and the side effects that come with it.

SDG 3 · Good health and well-being — Mechanism: tech innovation